chufangao/CTO huggingface dataset:
Clinical trial NCT03976076: A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
Official title: A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients
Sponsor: Bio-Pharm Solutions Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty with patient recruitment due to COVID-19
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-15
Primary completion date: 2021-12-10
Completion date: 2021-12-10
Limitations and caveats: No limitations reported for the study.
Plan to share individual participant data: NO
Clinical trial NCT04748848: A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Official title: A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business objectives have changed.
Enrollment: 1.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-10-14
Primary completion date: 2022-03-09
Completion date: 2022-03-09
Plan to share individual participant data: YES
IPD sharing description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD time frame: See Plan Description
IPD access criteria: See Plan Description
Clinical trial NCT04344535: Convalescent Plasma vs. Standard Plasma for COVID-19
Official title: Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection
Sponsor: Stony Brook University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Insufficient eligible and consenting patients
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-08
Primary completion date: 2021-01-01
Completion date: 2021-02-01
Plan to share individual participant data: NO
Clinical trial NCT02968680: Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
Official title: Pilot Translational Study of Sonazoid-Enhanced Ultrasonography for Sentinel Lymph Node Mapping in Cutaneous Melanoma
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Insufficient accrual
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-26
Primary completion date: 2019-06-28
Completion date: 2020-01-09
Clinical trial NCT04148742: Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Official title: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma
Sponsor: Dizal Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Clinical development strategy adjustment, non-safety reason
Enrollment: 120.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2021-08-31
Primary completion date: 2023-07-31
Completion date: 2023-07-31
Plan to share individual participant data: NO
Clinical trial NCT01035099: RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
Official title: A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-11-30
Primary completion date: 2019-07-23
Completion date: 2022-09-30
Baseline population: 41 subjects were enrolled; One subject 1 later withdrew consent prior to randomization.
Plan to share individual participant data: NO
Clinical trial NCT04343248: Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Official title: A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
Sponsor: Romark Laboratories L.C. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study recruitment was halted prematurely as widespread vaccination of the study population made completion infeasible.
Enrollment: 190.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-12
Primary completion date: 2021-02-01
Completion date: 2021-02-01
Baseline population: The safety population includes all subjects who received at least one dose of study medication.
Limitations and caveats: It was no longer possible to enroll eligible participants in the trial after vaccines were distributed to residents of long-term care facilities. Therefore, enrollment was terminated before the planned enrollment was completed. Study results are summarized descriptively, but no statistical analyses were performed.
Clinical trial NCT04970407: A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
Official title: A Phase I, Randomised, Double-blind, Parallel-group, Single-centre Comparative Study to Evaluate the Pharmacodynamic Profile of Dysport®, Botox®, and Xeomin® in the Extensor Digitorum Brevis (EDB) Model in Healthy Adult Male Participants
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 45.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-06
Primary completion date: 2022-03-16
Completion date: 2022-06-08
Baseline population: The Randomized set consisted of all participants who were randomized to study treatment. A participant was considered as randomized if a study intervention group was randomly assigned.
Plan to share individual participant data: NO
Clinical trial NCT03809455: Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
Official title: Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
Acronym: FARADI
Sponsor: UNICANCER (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study was cancelled by Sponsor.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-01
Primary completion date: 2022-02-01
Completion date: 2023-02-01
Clinical trial NCT04163328: Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort
Official title: Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID disruptions to recruitment and study completion, unforeseen staffing and other issues
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-16
Primary completion date: 2024-08-21
Completion date: 2024-08-21
Plan to share individual participant data: NO
Clinical trial NCT05039931: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
Official title: An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: leading entity of the clinical trial was replaced, and no patients were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-15
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Plan to share individual participant data: NO
Clinical trial NCT05429788: Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
Official title: A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Study to Evaluate the Safety, Tolerability, and Efficacy of Two Doses of RLS103 (CBD Technosphere® Inhalation Powder) in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
Sponsor: Receptor Life Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Lack of enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-05-18
Primary completion date: 2022-11-08
Completion date: 2022-11-08
Plan to share individual participant data: NO
Clinical trial NCT01239095: Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection
Official title: Perioperative Administration of Oral Green Tea Extract/Milk Thistle Extract to Colorectal Cancer Patients Undergoing Colorectal Cancer Resection, a Phase 1 Study
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-07-31
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT05367843: A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins
Official title: A Phase 1, Dose Ranging Study Assessing the Safety, Tolerability, Immunogenicity of Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV-2 Spike and Nucleocapsid Proteins (ORFEUS Study)
Sponsor: Speransa Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 103.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-06-20
Primary completion date: 2023-07-18
Completion date: 2023-11-08
Clinical trial NCT04171141: Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Official title: A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was terminated due to strategic considerations and not due to safety.
Enrollment: 79.0 (ACTUAL)
Number of arms: 7.0
Start date: 2019-11-19
Primary completion date: 2023-11-28
Completion date: 2023-11-28
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05118763: Intranasal INNA-051 for Prevention of COVID-19 in Adults
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Intranasal INNA-051 for Prevention of COVID-19 in Adults Following Close Contact With Individuals With SARS-CoV-2 Infection
Sponsor: ENA Respiratory Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-03-01
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
IPD sharing description: No plan
Clinical trial NCT05176925: Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
Official title: A Phase II, Open-Label, Single-Arm, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Consolidation Treatment in Patients With Locally Advanced, Unresectable NSCLC Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy
Sponsor: Fudan University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The trial was terminated per sponsor recommendation
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-10
Primary completion date: 2022-06-27
Completion date: 2022-09-28
Clinical trial NCT04416399: STerOids in COVID-19 Study
Official title: Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation
Acronym: STOIC
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Independent statistical review advice
Enrollment: 146.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-16
Primary completion date: 2021-01-12
Completion date: 2021-01-12
Plan to share individual participant data: NO
Clinical trial NCT03309514: Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease
Official title: Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease
Sponsor: NeuroGeneration (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Insufficient funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-30
Primary completion date: 2023-12-31
Completion date: 2024-06-30
Clinical trial NCT01882803: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
Official title: A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma
Acronym: DYNAMO
Sponsor: SecuraBio (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 129.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-06-17
Primary completion date: 2020-11-18
Completion date: 2020-11-18
Baseline population: Full Analysis Set (FAS): all participants who received at least 1 dose of duvelisib.
Clinical trial NCT04944654: Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH
Official title: Efficacy, Tolerability and Acceptability of the Single Table Regimen (STR) Biktarvy® by Trans People Living With HIV (TPLWH)
Sponsor: Chelsea and Westminster NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Trial set up was delayed, funding support no longer available
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-01-07
Primary completion date: 2023-05-11
Completion date: 2023-05-11
Plan to share individual participant data: NO
Clinical trial NCT03929640: Management Of Pain After Cesarean Trial
Official title: Management Of Pain After Cesarean Trial
Acronym: MOPAC
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lead co-I left institution in 2020 and enrollment was suspended. Study was kept open in hopes of finding a replacement/meeting enrollment goal, but a new lead was not found. Study is now officially closed.
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-05
Primary completion date: 2020-03-14
Completion date: 2020-03-26
Baseline population: Eligible subjects who received study drug
Limitations and caveats: Enrollment was suspended when the co-investigator responsible for study recruitment left the institution in 2020. At that time, only 49 subjects had been randomized (study enrollment goal was 150 subjects). The PI kept the study open but was not successful in finding a replacement to lead the study so it was eventually terminated.
Plan to share individual participant data: NO
IPD sharing description: May collaborate with PSU Addiction Center to perform secondary analyses on data collected, including total opiate consumption and pain scores.
Clinical trial NCT03370120: Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
Official title: An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure
Enrollment: 406.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-27
Primary completion date: 2020-12-11
Completion date: 2020-12-11
Baseline population: The Safety Set (SS) consisted of all enrolled participants who were administered at least 1 dose of PSL, based on the first dose date from the first administration of study medication Case Report form (CRF).
Plan to share individual participant data: YES
IPD sharing description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Clinical trial NCT04348500: Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
Official title: A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-28
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Baseline population: Enrolled patients who received the initial dose of the IP were analyzed.
Limitations and caveats: Due to the small sample size, unable to assess statistical significance between the treatment and placebo group.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04017390: The Effect of Theraworx Foam in Carpal Tunnel Syndrome
Official title: The Effect of Theraworx Foam on the Cross-sectional Area of the Median Nerve in Patients With Carpal Tunnel Syndrome
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of Funding from Sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-01-01
Primary completion date: 2022-01-03
Completion date: 2022-01-03
Plan to share individual participant data: YES
IPD sharing description: The ultrasound measurements and PRO questionnaire scores will be shared with the sponsor Avadim Technologies at a minimum of approximately 60 day intervals throughout the study (1 year) and at the discretion of the PI. In addition, final data will be provided within 12 months of completion of last participant
IPD time frame: Updated at intervals of approximately 60 days (minimum) and as needed as determined by PI. Final data will be available approximately 12 months after completion of last participant and will be available for 9 to 12 months.
Clinical trial NCT03972709: A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Official title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
Acronym: GALLEGO
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).
Enrollment: 372.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-06-03
Primary completion date: 2022-10-27
Completion date: 2022-10-27
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT05519527: STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
Official title: A Phase 1 Study of Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) or Acute Myeloid Leukemia (AML)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: 0 patient accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-16
Primary completion date: 2023-02-15
Completion date: 2023-02-15